Details for Patent: 8,648,098
✉ Email this page to a colleague
Which drugs does patent 8,648,098 protect, and when does it expire?
Patent 8,648,098 protects ESBRIET and is included in two NDAs.
This patent has forty patent family members in thirty countries.
Summary for Patent: 8,648,098
Title: | Pirfenidone therapy and inducers of cytochrome P450 |
Abstract: | The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking. |
Inventor(s): | Bradford; Williamson Ziegler (Ross, CA), Szwarcberg; Javier (San Francisco, CA) |
Assignee: | Intermune, Inc. (Brisbane, CA) |
Application Number: | 13/326,971 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,648,098 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,648,098
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genentech Inc | ESBRIET | pirfenidone | CAPSULE;ORAL | 022535-001 | Oct 15, 2014 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING A STRONG CYP1A2 INDUCER | ⤷ Sign Up | |||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | DISCONTINUING SMOKING TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE | ⤷ Sign Up | |||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE | ⤷ Sign Up | |||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-002 | Jan 11, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE | ⤷ Sign Up | ||||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-002 | Jan 11, 2017 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | DISCONTINUING SMOKING TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,648,098
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | E523197 | ⤷ Sign Up | |||
Australia | 2010212488 | ⤷ Sign Up | |||
Brazil | 112012013155 | ⤷ Sign Up | |||
Canada | 2710014 | ⤷ Sign Up | |||
Chile | 2012000952 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |